Linezolid Pellets

(Product under development)
Linezolid PelletsLinezolid is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. A member of the oxazolidinone class of drugs, linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).

The main indications of linezolid are infections of the skin and soft tissues and pneumonia (particularly hospital-acquired pneumonia), although off-label use for a variety of other infections is becoming popular.

Linezolid is marketed under the trade names Zyvox (in the United States, United Kingdom, Australia, and several other countries), Zyvoxid (in Europe), and Zyvoxam (in Canada and Mexico). Generics are also available in India, such as Linospan.

Discovered in the 1990s and first approved for use in 2000, linezolid was the first commercially available 1,3-oxazolidinone antibiotic. As of 2009, it is the only marketed oxazolidinone, although others are in development.

As a protein synthesis inhibitor, it stops the growth of bacteria by disrupting their production of proteins. Although many antibiotics work this way, the exact mechanism of action of linezolid appears to be unique to the oxazolidinone class. Bacterial resistance to linezolid has remained very low since it was first detected in 1999, although it may be increasing.

When administered for short periods, linezolid is a relatively safe drug; it can be used in patients of all ages and in people with liver disease or poor kidney function. Common adverse effects of short-term use include headache, diarrhea, and nausea. Long-term use, however, has been associated with serious adverse effects; linezolid can cause bone marrow suppression and low platelet counts, particularly when used for more than two weeks.

If used for longer periods still, it may cause peripheral neuropathy (which can be irreversible), optic nerve damage, and lactic acidosis (a buildup of lactic acid in the body), all most likely due to mitochondrial toxicity.

Linezolid is quite expensive, as a course of treatment (20 tablets 600 mg) can cost between one and two thousand U.S. dollars; nonetheless, it appears to be more cost-effective than comparable antibiotics, mostly because of the possibility of switching from intravenous to oral administration as soon as patients are stable enough, without the need for dose adjustments.

Availble Form:
Linezolid Pellets
Linezolid Granules

Umang Pharmatech equipments used for production of Linezolid Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.


Linezolid Pellets
Systematic (IUPAC) Name
Linezolid Pellets
Identifiers
Linezolid Pellets
Chemical data
(S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
CAS number : 165800-03-3
ATC code : J01XX08
PubChem : CID 441401
DrugBank : DB00601
ChemSpider : 390139
UNII : ISQ9I6J12J
KEGG : D00947
ChEMBL : CHEMBL126
Formula : C16H20FN3O4
Mol. mass : 337.346 g/mol


* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
Extruder Spheronizer Email Us Umang Pharmatech
TESTIMONIAL